An interventional study of Conventional therapy plus nifedipine and Conventional therapy in Diastolic Heart Failure, sponsored by Demand Investigators. Status unknown at 1 site in Japan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2016-01-25.
Sponsored by Demand Investigators · Not applicable, Interventional, and Treatment
Patients with heart failure with preserved ejection fraction have a equally high risk for mortality and re-hospitalization as those with reduced ejection fraction. Effective management strategies are critically needed to be established for this type of heart failure. These patients have more hypertensive and ischemic etiology than those with reduced ejection fraction. The investigators hypothesis is that Ca channel blocker nifedipine can improve the heart failure clinical composite response endpoint compared with the conventional treatment in patients with heart failure with hypertension and/or coronary artery disease and preserved ejection fraction (>=50%) by echocardiography. This study is multi-center, prospective, randomized, open-label, and blinded-endpoint design.
5,697 studies on the registry are indexed under Heart Failure; 1,219 are open to participants now.
This study's enrollment of 226 is above the median of 72 across 3,733 interventional studies indexed under Heart Failure.
Browse Heart Failure studies →This is the only study on the registry with Demand Investigators as lead sponsor.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Drug: Conventional therapy plus nifedipine
Drug: Conventional therapy
Participants will receive 10 to 60 mg of sustained-release nifedipine once a day until December 2014
Conventional therapy
Heart failure clinical composite response endpoint
Time frame: up to 53 months
Death
Time frame: up to 53 months
Cardiovascular death
Time frame: up to 53 months
Hospital admission
Time frame: up to 53 months
Hospital admission for cardiovascular disease
Time frame: up to 53 months
Hospital admission for worsening heart failure
Time frame: up to 53 months
Hospital admission for acute myocardial infarction, angina, coronary artery bypass grafting and percutaneous coronary intervention
Time frame: up to 53 months
Stroke
Time frame: up to 53 months
This study is status unknown, as verified in Jan 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.